Atlas Trials

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

Clinical trial NCT06214195 · RECRUITING

Trial details

NCT number
NCT06214195
Sponsor
Zhejiang Cancer Hospital
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Start date
2024-01-20
Primary completion
2026-12-01
Enrollment
276

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.